Cyclopharm Limited (AU:CYC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cyclopharm Limited has announced a significant partnership with the US Veterans Administration, securing an interim agreement to supply Technegas, a diagnostic product for lung diseases, to 120 VA hospitals. This deal is a precursor to broader inclusion in the US Federal Supply Schedule, expected to enhance care for conditions such as COPD and pulmonary fibrosis in veterans. Concurrently, Cyclopharm has also received its first Technegas order from the US Department of Defense, marking a strategic advancement in the company’s expansion within the largest nuclear medicine market.
For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.